Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018

Abstract Background Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, ICIs have been used clinically since 2015 for patients with advanced/metastatic NSCLC without epidermal gro...

Full description

Bibliographic Details
Main Authors: Andrea Wolf, Jan A. Stratmann, Shabnam Shaid, Nicolas Niklas, Alan Calleja, Harveen Ubhi, Robin Munro, Daniela Waldenberger, Robert Carroll, Melinda J. Daumont, John R. Penrod, Laure Lacoin, Gernot Rohde
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Pulmonary Medicine
Subjects:
Immune checkpoint inhibitors
Immunotherapy
Non-small cell lung cancer
Overall survival
Real-world evidence
Online Access:https://doi.org/10.1186/s12890-022-02288-1

Internet

https://doi.org/10.1186/s12890-022-02288-1

Similar Items